Himanshu Patni: Radioligand Therapy Market - Industry Size, Share, Growth & Forecast 2027

The global radioligand therapy market is expected to register a CAGR of around 4% over the period of 2021-2027. The radioligand therapy market is expected to register a CAGR of around 4% over the period of 2021-2027. This is mainly due to the rising prevalence of cancer, the surging geriatric population, growing hormonal disorders, and rising awareness regarding tumor treatment coupled with the growing focus of major stakeholders in the healthcare industry to adopt to make radioligand products more sustainable and eco-friendlier. Major pharmaceutical companies are investing heavily in their products due to rising cancer cases and the rising clinical research activity. As per the World Cancer Research Fund (WCRF), breast and lung cancers were the most common cancers worldwide, contributing 12.5% and 12.2% of the total number of new cases diagnosed in 2020. Prostate cancer was the fourth most common cancer with 1.4 million new cases in 2020, contributing 7.8% of new cases. Furthermore, various factors such as smoking, a high-fat diet, working with toxic chemicals, family history, inheritance, and genetics may play an important role in some childhood cancers also. Therefore, the market for radioligand therapy is expected to witness significant growth during the forecast period.

𝐓𝐨 𝐆𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐟𝐮𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 - https://univdatos.com/get-a-free-sample-form-php/?product_id=20939

According to UnivDatos Market Insights (UMI)’ research report “global radioligand therapy market”, the market is expected to witness robust growth during the forecast period 2021-2027F. This is mainly due to the increase in research laboratories, rise in prevalence of cancer, and increase in funding provided by governments. For instance, according to the world health organization, approximately 13% of cancers diagnosed in 2018 globally were attributed to carcinogenic infections, including Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus. These viruses risk liver and cervical cancer, respectively. Infection with HIV increases the risk of developing cervical cancer. Thus, research & development of radioligand therapy to treat a broad range of cancer types is expected to boost the global radioligand therapy treatment market during the forecast period. Furthermore, between 30 and 50% of cancers can currently be prevented by avoiding risk factors and implementing existing evidence-based prevention strategies. Many cancers have a high chance of cure if diagnosed early and treated appropriately. Therefore, the market for radioligand therapy is expected to witness a significant CAGR of 4% during the forecast period.

Based on product, the market is classified into approved products and potential pipeline. Amongst types, the approved products category accounted for a significant share of the market. This is mainly due to the presence of a wide range of products and the advent of novel and improved methods that are FDA-approved and more effective procedures such as lutetium 177, prostate-specific membrane antigen (PSMA), and other approved products for the treatment of cancer and development of the radioligand therapies. Furthermore, The United States is projected to lead the market during the forecast period, with a high rate of adoption of radioligand therapy products after FDA approval.

Based on indication, the market is categorized into prostate cancer, neuroendocrine tumor (NETs), and others. Among these, prostate cancer is expected to witness the highest CAGR during the forecast period. Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. However, the high cost of development of the radioligand therapies and the side effects associated with the treatment are expected to hinder the market growth over the forecast period.

North America to witness extensive growth

For a better understanding of the market adoption of the Radioligand Therapy industry, the market is analyzed based on its worldwide presence in the countries such as North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Spain, and Rest of Europe); Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), and Rest of World. North America is expected to witness a significant growth rate during the forecast period on account of the growing incidence of cancer which causes death in countries like the U.S. and Canada. The endorsement by FDA also significantly contributed to the considerable growth of the state in the U.S. radioligand therapy market. The Increase in awareness about radioligand therapy and the rise in the patient base suffering from cancer in the U.S. is expected to drive the market in the region. Furthermore, many medical and pharmaceutical companies are headquartered in the region, which is now focusing on research and development and clinical research activity for the treatment of cancer. Thus, the increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth.

For more informative information, please visit us – https://univdatos.com/report/radioligand-therapy-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the global Radioligand Therapy market are Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc., Bayer AG are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.

“Global Radioligand Therapy Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.

For more informative information, please visit us – https://univdatos.com/report/radioligand-therapy-market/

Market Segmentation:

1. By Product (Approved Products and Potential Pipeline)

2. By Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)

3. By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression, and Grading, Cytochrome P450 17A1 Inhibitor)

4. By Region (North America, Europe, Asia-Pacific, Rest of the World)

5. By Company (Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc., Bayer AG)

Key questions answered in the study:

1. What are the current and future trends of the global Radioligand Therapy industry?

2. How the industry has been evolving in terms of technology and application?

3. How the competition has been shaping across the countries followed by their comparative factorial indexing?

4. What are the key growth drivers and challenges for the global Radioligand Therapy industry?

5. What is the customer orientation, purchase behavior, and expectations from the global Radioligand Therapy suppliers across various region and countries?

Table of Content –

1 MARKET INTRODUCTION

2 RESEARCH METHODOLOGY OR ASSUMPTION

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL RADIOLIGAND THERAPY MARKET COVID-19 IMPACT

6 GLOBAL RADIOLIGAND THERAPY MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY PRODUCT

8 MARKET INSIGHTS BY INDICATION

9 MARKET INSIGHTS BY BIOMARKER

10 MARKET INSIGHTS BY REGION

11 RADIOLIGAND THERAPY MARKET DYNAMICS